TR200401962T4 - Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı - Google Patents

Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı

Info

Publication number
TR200401962T4
TR200401962T4 TR2004/01962T TR200401962T TR200401962T4 TR 200401962 T4 TR200401962 T4 TR 200401962T4 TR 2004/01962 T TR2004/01962 T TR 2004/01962T TR 200401962 T TR200401962 T TR 200401962T TR 200401962 T4 TR200401962 T4 TR 200401962T4
Authority
TR
Turkey
Prior art keywords
inhibitors
carboxamide derivatives
heteroaromatic carboxamide
ikk
enzyme
Prior art date
Application number
TR2004/01962T
Other languages
English (en)
Inventor
Baxter Andrew
Brough Stephen
Faull Alan
Johnstone Craig
Mcinally Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200401962T4 publication Critical patent/TR200401962T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bu icat, formül (I)'in heteroaromatik karboksamidler ile ilgilidir, burada A,R1,R2 ve X, bunlarin hazirlanmasinda kullanilan spesifikasyon, prosesler ve ara maddele, bunlari içeren farmasötik bilesimler ve bunlarin tedavideki kullanimlari seklinde tanimlanmaktadir.
TR2004/01962T 2000-02-12 2001-02-07 Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı TR200401962T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003154.2A GB0003154D0 (en) 2000-02-12 2000-02-12 Novel compounds

Publications (1)

Publication Number Publication Date
TR200401962T4 true TR200401962T4 (tr) 2004-09-21

Family

ID=9885396

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01962T TR200401962T4 (tr) 2000-02-12 2001-02-07 Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı

Country Status (21)

Country Link
US (2) US7358376B2 (tr)
EP (1) EP1261600B1 (tr)
JP (1) JP4812999B2 (tr)
KR (1) KR100738165B1 (tr)
CN (1) CN1243747C (tr)
AT (1) ATE266019T1 (tr)
AU (1) AU781047B2 (tr)
BR (1) BR0108143A (tr)
CA (1) CA2396824C (tr)
DE (1) DE60103132T2 (tr)
DK (1) DK1261600T3 (tr)
ES (1) ES2218376T3 (tr)
GB (1) GB0003154D0 (tr)
IL (2) IL150482A0 (tr)
MX (1) MXPA02007734A (tr)
NO (1) NO327741B1 (tr)
NZ (1) NZ519947A (tr)
PT (1) PT1261600E (tr)
TR (1) TR200401962T4 (tr)
WO (1) WO2001058890A1 (tr)
ZA (1) ZA200205300B (tr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1324759A4 (en) * 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
ES2305125T3 (es) 2000-10-26 2008-11-01 Amgen Inc. Agentes anti-inflamatorios.
PL364111A1 (en) * 2001-02-01 2004-12-13 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
US6881741B2 (en) * 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1444207A2 (en) * 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
ATE404550T1 (de) * 2001-09-21 2008-08-15 Smithkline Beecham Corp Chemische verbindungen
EP1436265A4 (en) 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
WO2003028731A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
EP1448545B1 (en) * 2001-10-04 2008-11-19 Smithkline Beecham Corporation Nf-kb inhibitors
JP2005509645A (ja) * 2001-10-30 2005-04-14 ファルマシア・コーポレーション 炎症処置用のヘテロ芳香族カルボキサミド誘導体
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
DE60325051D1 (de) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
US7179836B2 (en) 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
AU2003300832A1 (en) * 2002-12-06 2004-06-30 Smithkline Beecham Corporation NF-KappaB INHIBITORS
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
DE602004017478D1 (de) 2003-08-15 2008-12-11 Astrazeneca Ab Substituierte thiophene und deren verwendungen
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CA2541667A1 (en) * 2003-10-14 2005-04-21 Pharmacia Corporation Substituted pyrazinone compounds for the treatment of inflammation
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
ATE501138T1 (de) * 2004-01-05 2011-03-15 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
EP1764367A1 (en) * 2004-04-12 2007-03-21 Sankyo Company, Limited Thienopyridine derivatives
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
WO2006036031A1 (ja) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited 縮合フラン誘導体およびその用途
JP5000490B2 (ja) 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
AR055343A1 (es) 2005-06-30 2007-08-22 Smithkline Beecham Corp Derivados de indolcarboxamida inhibidores de quinasas ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2653654A1 (en) 2006-06-06 2007-12-21 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
JP5290186B2 (ja) * 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
JP5070067B2 (ja) * 2007-01-15 2012-11-07 参天製薬株式会社 ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN102089281A (zh) 2008-07-14 2011-06-08 参天制药株式会社 具有氨基甲酰基、脲基及取代氧基的新型吲哚衍生物
JP2010077119A (ja) * 2008-08-25 2010-04-08 Santen Pharmaceut Co Ltd ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤
EP2319831A4 (en) * 2008-08-25 2012-10-24 Santen Pharmaceutical Co Ltd NOVEL PYRROLE DERIVATIVE WITH A UREID GROUP, AN AMINOCARBONYL GROUP AND A BIZYCLIC GROUP EQUIPPED WITH A SUBSTITUENT AS SUBSTITUENTS
KR101693901B1 (ko) * 2008-11-14 2017-01-06 이 아이 듀폰 디 네모아 앤드 캄파니 비-수화가능한 결정 형태의 제조 방법
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
JP2012176930A (ja) * 2010-10-07 2012-09-13 Santen Pharmaceut Co Ltd ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP3040336B1 (en) 2012-03-02 2020-04-08 Sareum Limited Compounds for use in treating tyk2 kinase mediated conditions
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
EP0912548A1 (en) * 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
EP1324759A4 (en) * 2000-10-12 2004-05-12 Smithkline Beecham Corp NF - G (K) B INHIBITORS
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1448545B1 (en) * 2001-10-04 2008-11-19 Smithkline Beecham Corporation Nf-kb inhibitors
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NZ519947A (en) 2004-05-28
CA2396824C (en) 2010-11-16
US20090181962A1 (en) 2009-07-16
KR100738165B1 (ko) 2007-07-10
DK1261600T3 (da) 2004-08-16
DE60103132D1 (de) 2004-06-09
AU781047B2 (en) 2005-05-05
AU3070501A (en) 2001-08-20
ZA200205300B (en) 2003-10-02
MXPA02007734A (es) 2002-10-11
US7358376B2 (en) 2008-04-15
NO20023786L (no) 2002-09-23
DE60103132T2 (de) 2005-05-12
PT1261600E (pt) 2004-08-31
KR20030005183A (ko) 2003-01-17
JP2003522766A (ja) 2003-07-29
WO2001058890A1 (en) 2001-08-16
JP4812999B2 (ja) 2011-11-09
CN1243747C (zh) 2006-03-01
NO327741B1 (no) 2009-09-14
BR0108143A (pt) 2003-01-21
EP1261600A1 (en) 2002-12-04
IL150482A (en) 2006-08-01
NO20023786D0 (no) 2002-08-09
ATE266019T1 (de) 2004-05-15
CA2396824A1 (en) 2001-08-16
US20020107252A1 (en) 2002-08-08
ES2218376T3 (es) 2004-11-16
GB0003154D0 (en) 2000-04-05
CN1425012A (zh) 2003-06-18
IL150482A0 (en) 2002-12-01
EP1261600B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
TR200401962T4 (tr) Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı
CY1111543T1 (el) Νεες ενωσεις
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
MXPA04000755A (es) Nuevos compuestos.
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
SE0300092D0 (sv) Novel compounds
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
MXPA03003466A (es) Derivados de piranosido.
UA38786A (uk) Фібринолітичний засіб